Dr. Daniel Weiss MD
President, Weiss Consulting Groups, Inc.
Member of the Healthcare Council
Council Member Biography
Daniel Weiss, MD, FACC, is a Clinical Cardiac Electrophysiologist with Florida Arrhythmia Consultants and the Founder and President of his own consultancy, Weiss Consulting Groups, which provides consultation services to the business world on medical topics and to medical drug and device startup companies. He is currently the Chief Medical Officer for Vicor Medical Technologies, specializing in Medical Devices and Supplies. Through Dr. Weiss’ work as a consultant he has worked as Chief Medical Officer of a startup biotech company, Chief Medical Advisor of an engineering and software consulting firm, and chief cardiology advisor to a pharmaceutical corporation. He has been an investigator on numerous studies, including AVID, MADIT II, SCD-HeFT, as well as several other NIH studies. Dr. Weiss also serves as a consultant to several implantable cardiac device companies, including Medtronic, St Jude, and Guidant. (This is me - Update Profile)
Employment History
- 1996 - Unspecified
- President, Weiss Consulting Groups, Inc.
- 1994 - Unspecified
- Clinical Cardiac Electrophysiologist , ARRHYTHMIA CONSULTANTS FLORIDA PA
GLG NewsSM Analyses by Daniel Weiss
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
October 18, 2007
Medtronic Pulls Heart Device Wires | www.thestreet.com
The current recall is yet another in the world of cardiac rhythm devices. The ICD market is already shakey and may be adversely affected. Will Medtronic's reputation suffer?
-
TB-402 - the type of anticoagulant patients and physicians are looking for as a warfarin replacement
September 17, 2007
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 | www.pipelinereview.com
TB-402 is a new anticoagulant candidate that seeks to fill a desperate unmet need in a variety of different medical conditions. It would be easily administered with a low risk of patient noncompliance, have reversible effects, and potentially safer than currently available alternatives.
GLG Study Groups with Daniel Weiss(?)
| Study Group Name | No. Members |
|---|---|
| Heart Failure Specialists (US) | 1083 |
| Physicians who Treat Hypertension (US) | 949 |
| Medical Device Experts | 513 |
| Medical Tourism Experts | 350 |
| Physicians who Treat Arrhythmia (US) | 322 |
GLG Live Meetings with Daniel Weiss(?)
Daniel Weiss has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.